- ►prsjournal.com JF Arevalo, M Maia, HW Flynn, M Saravia, RL … - British Journal of Ophthalmology, 2008 - bjo.bmj.com Results: Eleven eyes (patients) out of 211 intravitreal injections (5.2%) that
developed or had progression of TRD were identified. All eyes had PDR refractory
to panretinal photocoagulation (PRP). Nine patients had type 1 diabetes ... Cited by 36 - Related articles - BL Direct - All 5 versions
- ►prsjournal.com [PDF] E Chen, CH PARK - Retina, 2006 - journals.lww.com Retinal neovascularization rarely occurs in association with choroidal
hemangioma.1 Shields et al2 studied the clinical manifestations of 200
consecutive cases of circumscribed choroidal hemangioma and observed a ... Cited by 67 - Related articles - BL Direct - All 4 versions
S Rizzo, F Genovesi-Ebert, E Di Bartolo, A … - Graefe's Archive for Clinical and Experimental …, 2008 - Springer Abstract Purpose To evaluate the use of preoperative intravitreal bevacizumab
(IVB) in patients undergoing pars plana vitrectomy (PPV) for complications of
proliferative diabetic retinopathy (PDR). Methods We studied 22 patients ... Cited by 16 - Related articles - BL Direct - All 2 versions
K Ishikawa, S Honda, Y Tsukahara, A Negi - Eye, 2007 - nature.com All cases showed minimum bleeding during surgical dissection of fibrovascular
membrane. Two cases receiving bevacizumab 7 days before the surgery showed
strong fibrosis and adhesion of fibrovascular membrane, resulted in some ... Cited by 20 - Related articles - All 3 versions
S Moradian, H Ahmadieh, M Malihi, M … - Graefe's Archive for Clinical and Experimental …, 2008 - Springer Abstract Background Vitreous concentration of vascular endothelial growth factor
(VEGF) rises significantly during prolifera- tive diabetic retinopathy (PDR).
Bevacizumab (Avastin) is a humanized monoclonal antibody to VEGF. ... Cited by 11 - Related articles - All 2 versions
M Shimura, T Nakazawa, K Yasuda, T Shiono, … - American journal of ophthalmology, 2008 - Elsevier Before the injection, foveal thickness and VA were 522.3 ± 91.3 μm and 0.64 ±
0.28 μm in the triamcinolone-injected eye, and 527.6 ± 78.8 μm and 0.61 ±
0.18 μm in the bevacizumab-injected eye, respectively; there was no ... Cited by 36 - Related articles - All 34 versions
JF Arevalo, L Wu, JG Sanchez, M Maia, MJ … - Eye, 2007 - nature.com Forty-four eyes of 33 patients with PDR and a mean age of 57.2-years (range:
23–82 years) participated in the study. Thirty-three eyes (75%) had previous
panretinal photocoagulation (PRP). Twenty-seven eyes (61.4%) showed total ... Cited by 17 - Related articles - All 3 versions
[CITATION] JF Arevalo, L Wu 2, JG Sanchez, M Maia 3
A Minnella, C Savastano, L Ziccardi, A Scupola … - Acta Ophthalmologica, 2008 - interscience.wiley.com Methods: This interventional case series study included 15 eyes of 10 patients
with bilateral PDR: 13 eyes with severe PDR and active new vessels (NV) and two
eyes with recurrent vitreous haemorrhages. Study eyes received a single ... Cited by 15 - Related articles - All 3 versions
CM Yang, PT Yeh, CH Yang, MS Chen - American Journal of Ophthalmology, 2008 - Elsevier Sixteen eyes (15 patients) that underwent primary pars plana vitrectomy for
active proliferative diabetic retinopathy (PDR) were prospectively enrolled with
a follow-up period of six months or more. These cases received an ... Cited by 8 - Related articles - All 23 versions
